NCT03880682

Direct Acting Antivirals for HCV Infection in Kidney Transplant Recipients

Treatment of Chronic Hepatitis C Virus Infection With Direct Acting Antivirals in Kidney Transplant Recipients

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 30 (actual)
• Sponsor: Istanbul University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Chronic hepatitis C virus (HCV) infection, an important cause of morbidity and mortality worldwide, is a significant problem in kidney transplant recipients (KTRs) given its high prevalence in patients undergoing hemodialysis. Interferon based regimens were cornerstone of treatment of HCV infection in the past; however, due to their low efficacy and high rates of adverse effects, they have been abandoned in the new era of direct acting antivirals (DAAs). Several studies demonstrated the efficacy and safety of DAAs, yet data regarding clinical practice of these agents in KTRs is still needed. Therefore, we conducted a study using our registry data to evaluate the efficacy and safety of DAAs in KTRs.

Conditions

• Kidney Transplant; Complications
• Hepatitis C, Chronic

Timeline

• Start date: 2018-11-01
• Primary completion: 2019-06-15
• Completion: 2019-10-31
• First posted: 2019-03-19
• Last updated: 2019-11-12

Locations

1 site across 1 country: Turkey (Türkiye)